HUTCHMED (China) (HCM) Other Non-Current Liabilities (2015 - 2025)
HUTCHMED (China)'s (HCM) quarterly Other Non-Current Liabilities came in at $13.2 million in Q4 2025, up 358.53% year-on-year from $2.9 million in Q4 2024, and down 85.81% on a QoQ basis from $93.0 million in Q2 2025.
HUTCHMED (China) (HCM) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
HUTCHMED (China) (HCM) has 11 years of Other Non-Current Liabilities data on file, last reported at $13.2 million in Q4 2025.
- On a quarterly basis, Other Non-Current Liabilities rose 358.53% year-over-year to $13.2 million in Q4 2025; TTM through Dec 2025 was $13.2 million, a 358.53% increase from a year earlier, with the FY2025 full-year figure at $89.3 million, up 2016.78% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $13.2 million, down from $93.0 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for HCM reached as high as $2.8 billion in Q4 2023 and fell as low as $2.9 million in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $275.6 million across 5 years, with a median of $13.2 million in 2025.
- Across the five-year window, Other Non-Current Liabilities soared 88088.42% in 2023 and sank 99.9% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $7.0 million in 2021, then plunged by 53.73% to $3.2 million in 2022, then jumped by 88088.42% to $2.8 billion in 2023, then slumped by 99.9% to $2.9 million in 2024, then soared by 358.53% to $13.2 million in 2025.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $13.2 million in Q4 2025, $93.0 million in Q2 2025, and $2.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | HUTCHMED (China) | 241.90 Mn | 243.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.21 Mn |
| Jun 30, 2025 | 93.04 Mn |
| Dec 31, 2024 | 2.88 Mn |
| Jun 30, 2024 | 19.31 Mn |
| Dec 31, 2023 | 2.84 Bn |
| Jun 30, 2023 | 19.29 Mn |
| Dec 31, 2022 | 3.22 Mn |
| Jun 30, 2022 | 20.21 Mn |
| Dec 31, 2021 | 6.96 Mn |
| Jun 30, 2021 | 5.52 Mn |
| Mar 31, 2021 | 6.81 Mn |
| Dec 31, 2020 | 8.78 Mn |
| Jun 30, 2020 | 9.01 Mn |
| Dec 31, 2019 | 5.96 Mn |
| Sep 30, 2019 | 7.46 Mn |
| Jun 30, 2019 | 7.86 Mn |
| Mar 31, 2019 | 8.33 Mn |
| Dec 31, 2018 | 2.40 Mn |
| Jun 30, 2018 | 2.85 Mn |
| Dec 31, 2017 | 1.12 Mn |